OTCMKTS:CYTR LadRx (CYTR) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free CYTR Stock Alerts $0.09 0.00 (0.00%) (As of 10/5/2022) Add Compare Share Share Today's Range$0.09▼$0.1050-Day Range$0.09▼$0.0952-Week Range$0.05▼$0.86Volume4,000 shsAverage Volume99,706 shsMarket Capitalization$4.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get LadRx alerts: Email Address Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About LadRx Stock (OTCMKTS:CYTR)LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.Read More CYTR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTR Stock News HeadlinesAugust 11, 2023 | finance.yahoo.comLadRx Corporation (LADX) Stock Historical Prices & Data - Yahoo FinanceNovember 27, 2022 | finance.yahoo.comLadRx Corporation Issues Corporate Update for 3Q22April 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.October 5, 2022 | businesswire.comLadRx Corporation Announces OTCQB Ticker Change to LADX - Business WireSeptember 23, 2022 | marketscreener.comCYTRX CORP : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comSeptember 23, 2022 | businesswire.comCytRx Corporation Relaunches as LadRx Corporation - Business WireSeptember 7, 2022 | businesswire.comEuropean Patent Office Awards CytRx Key Patent - Business WireAugust 25, 2022 | marketscreener.comADIAL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.comApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.August 21, 2022 | reuters.comCYTR.PK - CytRx Corporation | Stock Price & Latest News | ReutersAugust 9, 2022 | businesswire.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors - Business WireAugust 9, 2022 | finance.yahoo.comCytRx Welcomes Cary J. Claiborne to the CytRx Board of DirectorsJuly 27, 2022 | marketscreener.comCYTRX CORP : Submission of Matters to a Vote of Security Holders (form 8-K) - Marketscreener.comMay 20, 2022 | stockhouse.com2022-05-19 | OTCQB:CYTR | Press Release | CytRx Corporation - StockhouseMay 20, 2022 | businesswire.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Business WireMay 20, 2022 | marketscreener.comCYTRX CORP : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) - Marketscreener.comMay 19, 2022 | finance.yahoo.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Yahoo FinanceMay 19, 2022 | marketscreener.comCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock - Marketscreener.comMay 17, 2022 | finance.yahoo.comCytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.May 16, 2022 | streetinsider.comArcellx (ACLX) Appoints Olivia Ware to its Board - StreetInsider.comApril 20, 2022 | businesswire.comCytRx Partners with Oncology Development Expert to Advance LADR Platform - Business WireApril 20, 2022 | finance.yahoo.comCytRx Partners with Oncology Development Expert to Advance LADR PlatformApril 13, 2022 | prnewswire.comGene Therapies & Associated Vectors 2022: Intellectual Property Landscape, Patent Valuation Analysis, Granted Patents and Claims Analysis - PR NewswireMarch 25, 2022 | streetinsider.comForm 424B3 CYTRX CORP - StreetInsider.comMarch 23, 2022 | benzinga.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Benzinga - BenzingaMarch 23, 2022 | marketscreener.comCYTRX CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.comMarch 21, 2022 | finance.yahoo.comCytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress - Yahoo FinanceSee More Headlines Receive CYTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2019Today4/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CYTR CUSIPN/A CIK799698 Webwww.cytrx.com Phone(310) 826-5648Fax310-826-6139Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.61% Return on Assets-45.39% Debt Debt-to-Equity RatioN/A Current Ratio5.94 Quick Ratio5.94 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / BookN/AMiscellaneous Outstanding Shares45,037,000Free Float33,834,000Market Cap$4.14 million OptionableNot Optionable Beta1.96 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. John Y. Caloz (Age 70)CFO, Treasurer & Sr. VP Comp: $500kDr. Stephen Snowdy Ph.D. (Age 52)Chief Exec. Officer Molly Carey PoarchGlobal & U.S. Head of Corp. CommunicationsMs. Molly Painter (Age 46)Pres of USA and Head of Launch & Commercial Operations Terri StevensChief Bus. OfficerMs. Cristina NewmanCorp. Sec.Dr. Felix Kratz Ph.D. (Age 59)Sr. VP, Drug Devel. More ExecutivesKey CompetitorsTRACON PharmaceuticalsNASDAQ:TCONFinch Therapeutics GroupNASDAQ:FNCHPharmaCyte BiotechOTCMKTS:PMCBDKiromic BioPharmaNASDAQ:KRBPPalisade BioNASDAQ:PALIView All Competitors CYTR Stock Analysis - Frequently Asked Questions How have CYTR shares performed in 2024? LadRx's stock was trading at $0.0920 at the beginning of 2024. Since then, CYTR shares have increased by 0.0% and is now trading at $0.0920. View the best growth stocks for 2024 here. How were LadRx's earnings last quarter? LadRx Co. (OTCMKTS:CYTR) released its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. When did LadRx's stock split? Shares of LadRx reverse split before market open on Wednesday, November 1st 2017. The 1-6 reverse split was announced on Friday, October 27th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 31st 2017. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of LadRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other LadRx investors own include Anavex Life Sciences (AVXL), Biopharmx (BPMX), Rexahn Pharmaceuticals (REXN), Idera Pharmaceuticals (IDRA), Arrowhead Pharmaceuticals (ARWR), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), Marinus Pharmaceuticals (MRNS) and How do I buy shares of LadRx? Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CYTR) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LadRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
